Prostate Carcinoma Clinical Trials in Los Angeles, California

7 studies are recruiting for prostate carcinoma in Los Angeles, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Longitudinal Advanced Prostate Cancer Cohort (LAPCC)

   This study examines information from patients with prostate cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). By collecting biological samples (like blood, urine, and tissue), and health information (such as treatment, di…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Los Angeles General Medical Center, Los Angeles, California

   Locations

   2 in total

   Run by

   University of Southern California

   See if you can join NCT06067295 on ClinicalTrials.gov

2. MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial

   This clinical trial studies how well a magnetic resonance imaging (MRI)-based machine learning approach (i.e., artificial intelligence [AI]) works as compared to radiologist MRI readings in detecting prostate cancer. One of the current methods used to help diagnose possible prostate cancer is perfo…

   Stage

   Not phased

   Ages

   20 and older

   Site

   USC / Norris Comprehensive Cancer Center, Los Angeles, California

   Run by

   University of Southern California

   See if you can join NCT07162194 on ClinicalTrials.gov

3. 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

   This exploratory study conducted under the RDRC program studies the biodistribution of 99mTc-PSMA-I\&S in patients with prostate cancer who undergo pelvic lymph node dissection. Prostate specific membrane antigen (PSMA)-targeted radio-guided surgery uses the preoperative intravenous administration …

   Stage

   EARLY_Phase 1

   Ages

   Any age

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT04857502 on ClinicalTrials.gov

4. Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

   This study evaluates how new magnetic resonance imaging (MRI) and artificial intelligence techniques improve the image quality and quantitative information for future prostate MRI exams in patients with suspicious of confirmed prostate cancer. The MRI and artificial intelligence techniques develope…

   Stage

   Not phased

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT04765150 on ClinicalTrials.gov

5. Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

   In advanced metastatic castration resistant prostate cancer (mCRPC) progressing after chemotherapy and androgen receptor (AR)-targeted therapy 177Lu-PSMA-617 is an effective treatment. 177Lu-PSMA-617 RLT is administered with a fixed schedule: 6 treatment cycles, administered every 6 weeks. However,…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT06216249 on ClinicalTrials.gov

6. Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

   This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen [PSMA] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cance…

   Stage

   EARLY_Phase 1

   Ages

   18 to 90

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT07164027 on ClinicalTrials.gov

7. An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

   This phase II trial evaluates how well flotufolastat F 18 positron emission tomography (PET)/computed tomography (CT) imaging works to detect cancer that remains (residual) or that has come back (recurrent) after the completion of focal therapy for prostate cancer. Flotufolastat F 18 is a radioacti…

   Stage

   Phase 2

   Ages

   18 to 90

   Site

   UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

   Run by

   Jonsson Comprehensive Cancer Center

   See if you can join NCT07185165 on ClinicalTrials.gov